A5002405541- Allergic Rhinitis and Sensitization
- Respiratory and Cough-Related Research
- Asthma and respiratory diseases
- Food Allergy and Anaphylaxis Research
- Diabetes and associated disorders
- Probiotics and Fermented Foods
- Toxin Mechanisms and Immunotoxins
- Pharmaceutical studies and practices
- Immunodeficiency and Autoimmune Disorders
- Gut microbiota and health
- Insect and Pesticide Research
Nationwide Children's Hospital
2023
Line Corporation (Japan)
2020
Toray Industries, Inc. (Japan)
2018
Abstract Background The SQ house dust mite ( HDM ) sublingual immunotherapy SLIT )‐tablet TO ‐203, Torii, Japan/ ALK , Denmark) treatment has been effective against respiratory allergic diseases in patients aged ≥12 years during European, Japanese, and North American trials. This trial was conducted to investigate the efficacy safety of this Japanese children (5‐17 years) with moderate‐to‐severe rhinitis AR ). Methods In randomized, double‐blind, placebo‐controlled trial, 458 were randomly...
BackgroundThe house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet is a treatment option for allergic rhinitis with/without conjunctivitis (AR/C) approved in adults worldwide and adolescents some countries.ObjectiveTo supplement existing adolescent HDM SLIT-tablet safety data by conducting the MT-18 trial adolescents.MethodsMT-18 (EudraCT:2020-000446-34) was phase 3, open-label, single-arm, 28-day of daily (12 SQ-HDM dose) European (12-17 years) with AR/C, or without asthma. The...
There is no consensus method to identify anaphylaxis in sublingual immunotherapy (SLIT) trials. Standardized Medical Dictionary for Regulatory Activities (MedDRA) queries (SMQs) are standardized groupings of MedDRA terms used drug safety monitoring.
Objective: The SQ house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet has demonstrated effective treatment of HDM-induced allergic asthma in patients 18 years or older European trials. This study investigated its safety and immunology profile Japanese adult with mild-to-moderate asthma. Methods: In this randomized, double-blind, placebo-controlled study, 48 were randomly assigned to a daily HDM SLIT-tablet placebo (3:1) for 14 d without an up-dosing regimen. Active groups comprised...
1-Kestose is a trisaccharide prebiotic that modifies immune responses in humans and rodents with allergic diseases by altering the intestinal microbiota. In present study, we examined effects of 1-kestose supplementation on microbiota, peripheral lymphocyte subsets, antibody production healthy dogs. Fecal IgA levels serum titers against rabies vaccine were not significantly affected supplementation. flow cytometric analysis, percentage T cells among total lymphocytes decreased, whereas B...